Skip to main content
An official website of the United States government
Government Funding Lapse
Because of a lapse in government funding, the information on this website may not be up to date, transactions submitted via the website may not be processed, and the agency may not be able to respond to inquiries until appropriations are enacted.

The NIH Clinical Center (the research hospital of NIH) is open. For more details about its operating status, please visit cc.nih.gov.

Updates regarding government operating status and resumption of normal operations can be found at opm.gov.

interleukin-2/interleukin-15 receptor agonist NL-201

An interleukin-2 (IL-2) and interleukin-15 (IL-15) receptor agonist with high binding affinity for the common heterodimeric receptor IL-2Rbeta-gamma, which is composed of the IL-2 receptor subunit beta (IL-2Rbeta; CD122) and IL-2 receptor subunit gamma (IL-2Rgamma; common gamma; CD132), and no binding affinity for the IL-2 receptor subunit alpha (IL-2Ralpha; CD25), with potential immunoregulatory and antineoplastic activities. Upon administration, IL-2/IL-15 receptor agonist NL-201 targets and binds to IL-2Rbeta-gamma on natural killer (NK) and T cells and activates IL-2Rbeta-gamma-mediated signaling. This induces the selective proliferation of CD8+ T cells and NK cells, enhances tumor cell killing and decreases tumor cell proliferation. NL-201 does not bind to IL-2Ralpha, thereby circumventing both the activation of immunosuppressive regulatory T cells (Tregs) and the exacerbation of vascular leak syndrome associated with recombinant human IL-2. IL-2 and IL-15 receptors are cytokine receptors that play key roles in the immune response.
Check for active clinical trials using this agentView this agent in the NCI Thesaurus
Synonym:IL-2/IL-15 receptor agonist NL-201
Code name:NL 201
NL-201
Search NCI's Drug Dictionary
Please enter up to 30 characters for your search